Medically reviewed by: Last updated: Reviewed for: Clinical accuracy, alignment with current obesity-medicine guidance and FDA labeling, and JumpstartMD treatment protocols.
In a Nutshell
In the largest clinical trials, people taking the highest doses of these medications lost a meaningful share of their starting body weight over roughly 14 to 18 months. On semaglutide (Wegovy®), the average was −14.9% of body weight at 68 weeks; on tirzepatide (Zepbound®), the average was −20.9% at 72 weeks for the 15 mg dose 1, 2. For someone who starts at 220 lb, those averages translate to roughly 33 lb and 46 lb, respectively — but the word average hides an enormous range, and your result depends on your dose, how long you stay on treatment, how your body responds, and what you do alongside the medication.
Weight loss on a GLP-1 is not linear. It typically starts slowly during the weeks your dose is being escalated, accelerates through the middle months, then slows and plateaus around month 12 to 15 as your body settles at a new, lower set point. A plateau is usually a sign the medication is doing its job — not a sign it has stopped working.
Two things matter most before you read the numbers below. First: these are projections, not promises. Trial averages describe groups, not individuals, and roughly 1 in 6 people are "slow responders" who lose little in the first three months yet still reach a clinically meaningful result by the end of the year 8. Second: real-world results tend to be lower than trial results — largely because people stop early or never reach an effective dose 4. That gap is precisely where medically supervised care changes the trajectory. For the bigger picture, start with our pillar guide to GLP-1 medications for weight loss.
What the Trials Actually Showed
The two anchor trials are STEP 1 (semaglutide 2.4 mg, the active ingredient in Wegovy® and Ozempic®) and SURMOUNT-1 (tirzepatide 5/10/15 mg, the active ingredient in Zepbound® and Mounjaro®). Both enrolled adults with obesity (or overweight plus a weight-related condition) who did not have diabetes, and both paired the medication with lifestyle support 1, 2. The difference between the two molecules is explained in detail in semaglutide vs. tirzepatide.
Here is what the average participant achieved at the trial endpoint, and what fraction crossed each weight-loss threshold:
| Medication (dose) | Trial | Duration | Mean weight loss | ≥5% lost | ≥10% lost | ≥15% lost | ≥20% lost |
|---|---|---|---|---|---|---|---|
| Semaglutide 2.4 mg (Wegovy®) | STEP 1 | 68 weeks | −14.9% | 86.4% | 69.1% | 50.5% | 32.0% |
| Tirzepatide 5 mg (Zepbound®) | SURMOUNT-1 | 72 weeks | −15.0% | 85% | — | — | — |
| Tirzepatide 10 mg (Zepbound®) | SURMOUNT-1 | 72 weeks | −19.5% | 89% | — | — | 50% |
| Tirzepatide 15 mg (Zepbound®) | SURMOUNT-1 | 72 weeks | −20.9% | 91% | — | — | 57% |
| Placebo (STEP 1) | STEP 1 | 68 weeks | −2.4% | 31.5% | 12.0% | 4.9% | 1.7% |
| Placebo (SURMOUNT-1) | SURMOUNT-1 | 72 weeks | −3.1% | 35% | — | — | 3% |
(Dashes mean the threshold was not separately reported in the trial's primary publication — not that it was zero.) 1, 2
A few things to read off this table. The dose matters: tirzepatide climbed from −15.0% to −20.9% as the dose rose from 5 to 15 mg 2. The medication matters too: in the only large head-to-head trial, SURMOUNT-5, the maximum tolerated dose of tirzepatide produced −20.2% versus −13.7% for semaglutide at 72 weeks 3. And the placebo column is not nothing — lifestyle support alone produced 2-3% loss, a reminder that the program around the drug does real work.
The Month-by-Month Trajectory
You will not lose weight at a steady pace, and knowing the shape of the curve in advance prevents the most common mistake: panicking during a slow stretch and abandoning treatment too soon. In STEP 1, measurable weight loss began around week 4 and continued until a low point (nadir) around week 60 — roughly month 14 — after which weight held steady 1. The dose-escalation schedule (about 16 weeks for semaglutide to reach 2.4 mg, about 20 weeks for tirzepatide to reach a maintenance dose) means the first few months are deliberately the slowest 9, 10. More on the ladder itself in dosing and titration.
| Phase | Approximate timeframe | What's happening | Typical pattern |
|---|---|---|---|
| Ramp-up (titration) | Months 0–4 | Dose climbs step by step; appetite suppression and "food noise" reduction build gradually; GI side effects most likely | Early, modest loss begins ~week 4; expect 5% or so, not dramatic numbers |
| Steepest loss | Months 3–9 | You reach an effective maintenance dose; appetite is reliably lower; the steepest part of the curve | The bulk of total loss usually happens here |
| Approaching plateau | Months 9–15 | Rate of loss slows; body adapts metabolically; nadir reached ~week 60 in STEP 1 | Loss decelerates — this is expected, not failure |
| Plateau / maintenance | Month 15+ | Weight stabilizes at a new set point | Continued treatment holds the loss; stopping tends to reverse it |
Does the loss last? In STEP 5, semaglutide held an average −15.2% at two years (104 weeks), so the plateau is a durable new baseline, not a temporary dip 7. A plateau does not mean the drug "stopped working" — it means your intake and expenditure have re-balanced at a lower weight. If you've truly stalled well short of your goal for months, that's a conversation about dose, adherence, and muscle preservation — not a reason to quit.
What "Average" Hides: The Responder Spread
The single most important thing to understand about a trial average is that it is the midpoint of a wide spread. Some people lose 30% of their body weight; others lose very little. Looking only at the headline number sets you up to misjudge your own early progress.
A post-hoc analysis of SURMOUNT-1 sorted tirzepatide users by their 12-week response. About 82% were "early responders" (≥5% lost by week 12) and 18% were "late responders" (<5% by week 12). Here's the encouraging part: 90% of those slow-starting late responders still reached at least 5% weight loss by week 72, and on average it took them about 25 weeks to get there 8. In other words, a quiet first three months frequently still ends in a meaningful result — provided treatment continues.
| Early response group (tirzepatide, SURMOUNT-1) | Share of patients | Reached ≥5% loss by week 72 |
|---|---|---|
| Early responders (≥5% by week 12) | 82% | Nearly all |
| Late responders (<5% by week 12) | 18% | 90% (mean ~25 weeks to reach 5%) |
There is also a smaller group of genuine non-responders — across the trials, roughly 9-15% of patients did not reach 5% loss even at the higher doses 1, 2. If that's you after an adequate trial at an effective dose, it's useful clinical information — a reason to re-evaluate with a clinician (a different medication, a switch, or a workup for other contributors), not to assume failure.
Trial Results vs. the Real World
Clinical-trial numbers are achieved under near-ideal conditions: free medication, frequent visits, structured coaching, and strong incentives to reach the maximum tolerated dose. Outside trials, results are typically lower — and the reasons are instructive.
In a large real-world cohort, average weight loss at one year was about 8.7%, well below the trial figures 4. But that average collapses several very different outcomes:
| Real-world adherence pattern | Mean weight loss at 1 year |
|---|---|
| Stopped early (within 3 months) | 3.6% |
| Stopped later (3–12 months) | 6.8% |
| Stayed on treatment all year | 11.9% |
The story in those rows is adherence and dose, not biology. In the same real-world data, roughly 21% of people stopped within the first three months and most never reached an effective maintenance dose — compared with a 7-11% discontinuation rate in the trials 4. People who stayed on treatment did markedly better. This is the gap supervised care is designed to close: managing side effects so you don't quit during the rough titration weeks, titrating to a dose that actually works for you, and protecting the result over time. It's also why stopping a GLP-1 tends to bring weight back — in the STEP 1 off-treatment extension, participants regained about two-thirds of their lost weight in the year after stopping 5, and in SURMOUNT-4, withdrawing tirzepatide led to substantial regain while continued treatment kept the loss off 6.
Factors That Shift Your Curve
Your personal trajectory is pushed up or down by several levers — some you control, some your clinician manages, and some are biology:
- Dose and medication. Higher tolerated doses and the dual-agonist tirzepatide generally produce more loss than lower doses or semaglutide 2, 3. The target is the highest tolerated effective dose — not always the maximum dose (dosing and titration).
- Staying on treatment long enough. The curve doesn't reach its nadir until around month 14; stopping at month 3 captures only the slow opening phase 1, 4.
- Protecting muscle. Without attention to protein and resistance training, a substantial share of the weight lost can be lean mass rather than fat — bad for metabolism and maintenance. Track body composition, not just the scale.
- Side-effect tolerance. If GI side effects force you to pause titration, your dose — and your loss — can stall with it.
- Starting weight. Percentage loss is fairly consistent across body sizes, but the pounds differ, and men and people with higher baseline weight sometimes respond more slowly early on 8.
- Hormonal context. Perimenopause and menopause shift metabolism and fat distribution; coordinated care for perimenopause weight gain and visceral fat can change the curve.
- Compounded vs. FDA-approved product. Inconsistent dosing from unregulated sources can blunt results; see compounded semaglutide safety.
Is Your Pace Normal? When to Talk to Your Clinician
Most of the time, "slow" is normal and "plateau" is success. But a few patterns are worth a conversation:
- Almost no change after you've reached an effective maintenance dose for 8-12 weeks. It may be time to reassess dose, adherence, or whether this medication is right for you.
- A sustained plateau far short of your health goals for several months — a prompt to review the whole plan, not to abandon it.
- Rapid, unintentional loss with inability to eat or drink, dizziness, or signs of dehydration — that's a tolerability and safety issue, not a "win." Don't push through it; call your clinician.
- New or severe symptoms — persistent vomiting, severe abdominal pain, or other warning signs belong in our serious side effects and red flags guide and may need urgent care.
Weight that comes off too fast, or comes off as muscle, is not better — it's a reason to involve your care team, who can adjust the pace and protect your body composition.
What You Can Do About It
You can't control your exact response, but you can stack the odds toward the upper end of the range.
Foundation (everyone):
- Hit a daily protein target and add resistance training 2-3 times a week — the highest-leverage way to keep loss pointed at fat instead of muscle.
- Stay hydrated and eat enough, especially during titration. Under-eating to "speed things up" backfires by accelerating muscle loss and worsening side effects.
- Track trends, not days. Weight fluctuates daily; watch the multi-week trajectory and, ideally, body-composition trends rather than a single reading.
Work with your clinician on:
- Reaching an effective dose at a pace your gut tolerates — patience through titration is what separates trial-level results from the real-world average 4.
- Re-evaluating a true plateau or non-response — possibly switching agents or adjusting the plan.
- Planning the long game, including maintenance dosing and, if you ever stop, a structured taper and step-down plan.
Dose changes, switches, and stopping decisions all belong with a clinician — not a forum or a guess. That supervision is the difference between the trial curve and the real-world curve.
Get Started with JumpstartMD
If you want results that look more like the trials and less like the real-world average, the difference is almost always supervision: reaching an effective dose, staying on it through the hard weeks, and protecting muscle while you lose fat.
JumpstartMD was founded in 2007 by Stanford-trained physicians, with programs built around labs, hormones, and body composition — and peer-reviewed outcomes published in the Journal of Obesity. You're seen face-to-face by licensed clinicians, either in person at 14 California locations or online across California. Care starts with a 69-biomarker lab screening and includes InBody® body-composition scanning at each visit — so we can confirm you're losing fat, not strength. That matters here: without supervision, up to 40% of the weight lost on a GLP-1 can be muscle, which is exactly the outcome that undermines a good-looking number on the scale.
We offer the full range of FDA-approved options — Ozempic®, Wegovy®, Zepbound®, Mounjaro®, and Rybelsus® — plus non-GLP-1 and no-medication plans, with clinician-managed titration, contraindication screening before any prescription, drug-interaction monitoring, restart protocols, and a step-down/taper plan to protect your results after the medication phase. Pricing is personalized — you pay for the dose prescribed, not a flat monthly medication fee — and health coaching and nutrition guidance are included in membership.
Curious where your own curve might land? Start with a free, no-obligation consultation by phone or form, and we'll map a plan to your starting point, your goals, and your tolerance.
Book FREE Consultation
Share your details and a JumpstartMD team member will reach out shortly. Or call 408.478.3496 for your free, no-obligation consultation.
Related Articles
- Semaglutide vs. tirzepatide — the head-to-head efficacy comparison behind the dose differences in the tables above.
- Preventing muscle loss on GLP-1s — how to make sure the weight you lose is fat, not lean mass, which shapes both your results and your maintenance.
- Stopping GLP-1s and weight regain — what happens to the curve when treatment ends, and how a taper protects it.
- GLP-1 dosing and titration — why the first months are slow by design and how the dose ladder drives the trajectory.
- GLP-1s and menopause — how hormonal changes shift the weight-loss curve for women in midlife.
Frequently Asked Questions
How much weight will I lose on a GLP-1?
On average, trials showed about 15% of body weight lost on semaglutide (Wegovy®) over 68 weeks and up to 21% on the highest dose of tirzepatide (Zepbound®) over 72 weeks 1, 2. For a 220-lb starting weight, that's roughly 33-46 lb. But the average hides a wide range — some people lose far more, some far less, and roughly 1 in 6 are slow starters who still reach a meaningful result by the end of the year 8. Your number depends on dose, how long you stay on treatment, your individual response, and what you do alongside the medication. Treat these figures as projections, not promises.
How fast does weight come off on semaglutide or tirzepatide?
Not steadily. Measurable loss usually begins around week 4, but the first few months are deliberately slow because your dose is still being escalated 1, 9, 10. The steepest loss typically happens between roughly months 3 and 9, once you reach an effective maintenance dose, and then slows toward a plateau around month 12-15. The low point in STEP 1 came around week 60 — about 14 months in 1.
What does a weight-loss plateau on a GLP-1 mean?
A plateau usually means success, not failure — your body has settled at a new, lower set point and your intake and energy use have re-balanced. In STEP 5, the average loss held at about 15% even at two years, so the plateau is a durable new baseline 7. If you've genuinely stalled well short of your goals for several months, that's worth discussing with your clinician — it may be a dose, adherence, or body-composition issue rather than the medication "wearing off."
Why am I losing less than the numbers in the trials?
Real-world results are typically lower than trial results, and the main reasons are stopping early and never reaching an effective dose — not your biology 4. In a large real-world study, people who stayed on treatment all year lost about 12%, while those who stopped within three months lost under 4% 4. Managing side effects so you can stay on an effective dose is the single biggest lever, and it's exactly what supervised care is for.
Will I keep losing weight forever?
No — and you wouldn't want to. Weight loss reaches a low point and then plateaus as your body stabilizes, generally around month 12-15 1. Continued treatment maintains that loss; in withdrawal trials, stopping the medication led to substantial regain — about two-thirds of the lost weight within a year in the STEP 1 extension 5, and continued tirzepatide kept the loss off in SURMOUNT-4 6. The goal is reaching a healthier set point and then holding it, which is why a long-term maintenance and taper plan matters.
I've lost almost nothing in the first three months. Should I quit?
Probably not yet. In SURMOUNT-1, 90% of "late responders" — people who lost less than 5% by week 12 — still reached a meaningful result by week 72, taking about 25 weeks on average to get there 8. A quiet start often still ends well, especially as you reach an effective dose. The right move is to talk with your clinician about dose and tolerance, not to stop. If you remain a true non-responder after an adequate trial at an effective dose, that's useful information that may point to a different medication.
References
- J. P. H. Wilding, R. L. Batterham, S. Calanna, et al., "Once-weekly semaglutide in adults with overweight or obesity," New England Journal of Medicine, vol. 384, no. 11, pp. 989-1002, Mar. 2021, [Online]. Available: https://doi.org/10.1056/NEJMoa2032183. PMID: 33567185. [Accessed: Jun. 10, 2026]. ↩
- A. M. Jastreboff, L. J. Aronne, N. N. Ahmad, et al., "Tirzepatide once weekly for the treatment of obesity," New England Journal of Medicine, vol. 387, no. 3, pp. 205-216, Jul. 2022, [Online]. Available: https://doi.org/10.1056/NEJMoa2206038. PMID: 35658024. [Accessed: Jun. 10, 2026]. ↩
- L. J. Aronne, D. B. Horn, C. W. le Roux, et al., "Tirzepatide as compared with semaglutide for the treatment of obesity," New England Journal of Medicine, vol. 393, no. 1, pp. 26-36, Jul. 2025, [Online]. Available: https://doi.org/10.1056/NEJMoa2416394. PMID: 40353578. [Accessed: Jun. 10, 2026]. ↩
- H. Gasoyan, W. S. Butsch, R. Schulte, et al., "Changes in weight and glycemic control following obesity treatment with semaglutide or tirzepatide by discontinuation status," Obesity (Silver Spring), vol. 33, no. 9, pp. 1657-1667, Sep. 2025, [Online]. Available: https://doi.org/10.1002/oby.24331. PMID: 40491239. [Accessed: Jun. 10, 2026]. ↩
- J. P. H. Wilding, R. L. Batterham, M. Davies, et al., "Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension," Diabetes, Obesity and Metabolism, vol. 24, no. 8, pp. 1553-1564, Aug. 2022, [Online]. Available: https://doi.org/10.1111/dom.14725. PMID: 35441470. [Accessed: Jun. 10, 2026]. ↩
- L. J. Aronne, N. Sattar, D. B. Horn, et al., "Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial," JAMA, vol. 331, no. 1, pp. 38-48, Jan. 2024, [Online]. Available: https://doi.org/10.1001/jama.2023.24945. PMID: 38078870. [Accessed: Jun. 10, 2026]. ↩
- W. T. Garvey, R. L. Batterham, M. Bhatta, et al., "Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial," Nature Medicine, vol. 28, no. 10, pp. 2083-2091, Oct. 2022, [Online]. Available: https://doi.org/10.1038/s41591-022-02026-4. PMID: 36216945. [Accessed: Jun. 10, 2026]. ↩
- J. Ard, C. J. Lee, K. Gudzune, et al., "Weight reduction over time in tirzepatide-treated participants by early weight loss response: post hoc analysis in SURMOUNT-1," Diabetes, Obesity and Metabolism, vol. 27, no. 9, pp. 5064-5071, Sep. 2025, [Online]. Available: https://doi.org/10.1111/dom.16554. PMID: 40677091. [Accessed: Jun. 10, 2026]. ↩
- U.S. Food and Drug Administration, "Highlights of Prescribing Information: Wegovy (semaglutide) injection, for subcutaneous use," [Online]. Available: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215256s000lbl.pdf. [Accessed: Jun. 10, 2026]. ↩
- U.S. Food and Drug Administration, "Highlights of Prescribing Information: Zepbound (tirzepatide) injection, for subcutaneous use," [Online]. Available: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217806s000lbl.pdf. [Accessed: Jun. 10, 2026]. ↩
